| US FDA approves Amneal's migraine treatment |
Amneal Pharmaceuticals said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug. |
reuters.com |
2025-05-15 12:16:28 |
Czytaj oryginał (ang.) |
| Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults |
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya® (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.1,2 Brekiya autoinjector provides patients with the potential for sustained* pain relief† in a convenient, self-administered form.1 , 3 ,4 It contains the same medication (DHE) used in hospitals, now in a ready-to-use device.1, 5 Brekiya autoinjector does not require refrigeration, assembly, or priming of the device.1 Patients can deliver one dose subcutaneously into the middle of the thigh.1 This may be beneficial for patients who respond inadequately to oral therapies due to lack of efficacy, experience nausea or vomiting during attacks, have gastroparesis, or delay dosing until too late into the attack.1 ,5 ,6 “We are thrilled to offer the first and only ready-to-use autoinjector for patients suffering from acute migraine and cluster headaches. |
globenewswire.com |
2025-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-09 15:01:01 |
Czytaj oryginał (ang.) |
| Here is Why Growth Investors Should Buy Amneal (AMRX) Now |
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2025-05-08 17:45:39 |
Czytaj oryginał (ang.) |
| Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S. |
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal's extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), an American biopharmaceutical company, and Apiject Systems, Corp. (“Apiject”), a medical technology company focused on advanced drug delivery, today announced a strategic collaboration to expand domestic production of Apiject's BFS-based injectable platform at Amneal's Brookhaven, NY facility. |
globenewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript |
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Chris Schott - JPMorgan Operator Good morning and welcome to the Amneal Pharmaceuticals First Quarter 2025 Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo. |
seekingalpha.com |
2025-05-02 15:32:24 |
Czytaj oryginał (ang.) |
| Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-02 14:35:50 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates |
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago. |
zacks.com |
2025-05-02 12:10:37 |
Czytaj oryginał (ang.) |
| Amneal Reports First Quarter 2025 Financial Results |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS. |
businesswire.com |
2025-05-02 10:00:00 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? |
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-25 15:06:24 |
Czytaj oryginał (ang.) |
| Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month. |
businesswire.com |
2025-04-11 12:00:00 |
Czytaj oryginał (ang.) |
| Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® Extended-Release Capsules in Parkinson's Disease. |
businesswire.com |
2025-04-07 12:00:00 |
Czytaj oryginał (ang.) |
| Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. BORUZU™ (bortezomib injection), a pr. |
businesswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued |
Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively, targeting a net debt to EBITDA ratio of 3.6-3.7 in 2025, enhancing financial stability and investor confidence. |
seekingalpha.com |
2025-03-19 17:14:54 |
Czytaj oryginał (ang.) |
| Amneal to Participate at Upcoming Investor Conference |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference. |
businesswire.com |
2025-03-10 18:05:00 |
Czytaj oryginał (ang.) |
| Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA. |
businesswire.com |
2025-03-03 18:05:00 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript |
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President and Chief Commercial Officer, Specialty Jason Daly - Chief Legal Officer Conference Call Participants Chris Schott - J.P. Morgan David Amsellem - Piper Sandler Leszek Sulewski - Truist Securities Balaji Prasad - Barclays Operator Good morning and welcome to the Amneal Pharmaceuticals Fourth Quarter 2024 Earnings Call. |
seekingalpha.com |
2025-02-28 16:20:17 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Amneal (AMRX) Q4 Earnings |
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-28 12:30:36 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals (AMRX) Q4 Earnings Lag Estimates |
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago. |
zacks.com |
2025-02-28 10:15:28 |
Czytaj oryginał (ang.) |
| Amneal Reports Fourth Quarter and Full Year 2024 Financial Results |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Fourth Quarter and Full Year 2024 Financial Results. |
businesswire.com |
2025-02-28 08:00:00 |
Czytaj oryginał (ang.) |
| Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q4 Earnings |
Evaluate the expected performance of Amneal (AMRX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-02-25 12:20:42 |
Czytaj oryginał (ang.) |
| Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock? |
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-02-25 12:15:30 |
Czytaj oryginał (ang.) |
| Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock |
J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company's generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfolio. |
benzinga.com |
2025-02-24 15:42:44 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth |
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-21 13:00:36 |
Czytaj oryginał (ang.) |
| Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? |
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-02-06 15:11:10 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know |
The consensus price target hints at a 27.1% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-02-03 12:55:47 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era |
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio. |
zacks.com |
2025-01-31 11:05:28 |
Czytaj oryginał (ang.) |
| Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025. |
businesswire.com |
2025-01-29 10:30:00 |
Czytaj oryginał (ang.) |
| Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year? |
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year. |
zacks.com |
2025-01-16 12:40:33 |
Czytaj oryginał (ang.) |
| Amneal (AMRX) Upgraded to Strong Buy: Here's Why |
Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2025-01-08 15:00:37 |
Czytaj oryginał (ang.) |
| Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist. |
businesswire.com |
2024-11-21 18:05:00 |
Czytaj oryginał (ang.) |
| AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue? |
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-11-12 12:15:21 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript |
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Balaji Prasad - Barclays Bank Leszek Sulewski - Truist Securities Chris Schott - JPMorgan Operator Hello, everyone and thank you for your patience. The Amneal Pharmaceuticals Third Quarter 2024 Earnings Call will begin shortly. |
seekingalpha.com |
2024-11-08 17:27:09 |
Czytaj oryginał (ang.) |
| Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates |
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-11-08 12:36:20 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates |
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.19 per share a year ago. |
zacks.com |
2024-11-08 10:10:32 |
Czytaj oryginał (ang.) |
| Amneal Reports Third Quarter 2024 Financial Results |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Third Quarter 2024 Financial Results. |
businesswire.com |
2024-11-08 08:00:00 |
Czytaj oryginał (ang.) |
| Amneal (AMRX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures |
Evaluate the expected performance of Amneal (AMRX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2024-11-06 12:20:25 |
Czytaj oryginał (ang.) |
| 5 Stocks Backed by High Efficiency for Solid Gains Amid Volatility |
Invest in stocks of AMRX, CRON, CSV, BFST and APH to tap their high-efficiency levels. |
zacks.com |
2024-11-05 10:05:18 |
Czytaj oryginał (ang.) |
| Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline |
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-11-01 13:06:15 |
Czytaj oryginał (ang.) |
| How to Find Great Cheap Stocks Under $10 to Buy in October |
On top of their cheap price tags, Wall Street analysts are high on all of these stocks and their improving earnings outlooks earn them strong Zacks Ranks. |
zacks.com |
2024-10-15 20:01:16 |
Czytaj oryginał (ang.) |
| Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? |
Here is how Amneal Pharmaceuticals (AMRX) and Astrazeneca (AZN) have performed compared to their sector so far this year. |
zacks.com |
2024-10-14 14:40:57 |
Czytaj oryginał (ang.) |
| Amneal to Report Third Quarter 2024 Results on November 8, 2024 |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Third Quarter 2024 Results on November 8, 2024. |
businesswire.com |
2024-10-08 20:05:00 |
Czytaj oryginał (ang.) |
| Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases |
BRIDGEWATER, N.J. & NEW YORK--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and Metsera, Inc. (“Metsera”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that they have entered into a collaboration agreement to enable the efficient development and large-scale supply of a portfolio of new weight loss medicines globally. The col. |
businesswire.com |
2024-10-01 10:00:00 |
Czytaj oryginał (ang.) |
| Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease. |
businesswire.com |
2024-09-23 12:00:00 |
Czytaj oryginał (ang.) |
| Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates |
AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont. |
zacks.com |
2024-09-03 15:57:04 |
Czytaj oryginał (ang.) |
| Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock |
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. |
zacks.com |
2024-08-21 13:50:46 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Innovation Reaches Peak |
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio. |
zacks.com |
2024-08-16 13:20:29 |
Czytaj oryginał (ang.) |
| Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript |
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2024 Earnings Conference Call August 9, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Leszek Sulewski - Truist Securities Operator Good morning and welcome to the Amneal Pharmaceuticals Second Quarter 2024 Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo. |
seekingalpha.com |
2024-08-09 16:14:05 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-08-09 14:30:47 |
Czytaj oryginał (ang.) |
| AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out? |
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-08-09 14:15:56 |
Czytaj oryginał (ang.) |